Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–254. doi:10.3322/caac.21772
   PubMed Web of Science ®Google Scholar
• Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023;9(1):21. doi:10.1038/s41572-023-00432-7
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372–401. doi:10.3322/caac.21728
   PubMed Web of Science ®Google Scholar
• Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678–700. doi:10.1200/JCO.22.01690
   PubMed Web of Science ®Google Scholar
• Alice E, Shin F, Giancotti G, Anil K. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44.
   Web of Science ®Google Scholar
• Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44(4):222–236. doi:10.1016/j.tips.2023.01.003
   PubMed Web of Science ®Google Scholar
• Raghav K, Ou FS, Venook AP, et al. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol. 2023;41(3):472–478. doi:10.1200/JCO.22.00365
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070–1082. doi:10.1016/S1470-2045(19)30272-4
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61. doi:10.18553/jmcp.2003.9.1.53
   PubMedGoogle Scholar
• Spiegel BM, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology. 2004;127(2):403–411. doi:10.1053/j.gastro.2004.04.020
   PubMed Web of Science ®Google Scholar
• Cho SK, Hay JW, Barzi A. Cost-effectiveness Analysis of Regorafenib and Tas-102 in Refractory Metastatic Colorectal Cancer in the United States. Clin Colorectal Cancer. 2018;17(4):e751–e761. doi:10.1016/j.clcc.2018.08.003
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Ahmad BB, Chen Q, et al. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol. 2015;33(32):3727–3732. doi:10.1200/JCO.2015.61.9569
   PubMed Web of Science ®Google Scholar
• Cho SK, Bekaii-Saab T, Kavati A, Babajanyan S, Hocum B, Barzi A. Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US. Clin Colorectal Cancer. 2022;21(4):277–284. doi:10.1016/j.clcc.2022.09.003
   PubMed Web of Science ®Google Scholar
• Barzi A, Cho SK, Hay JW, et al. Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer. J clin oncol. 2019;37.
   Google Scholar
• Guan X, Li H, Xiong X, et al. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ. 2021;24(1):339–344. doi:10.1080/13696998.2021.1888743
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhou J, Ye Y, Wang X, Ma A, Li H. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China. Front Oncol. 2023;13:1113346. doi:10.3389/fonc.2023.1113346
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma AX, Li H, Rascati K. Pcn117 Cost-Effectiveness Analysis of Regorafenib Used in Chinese Patients with Metastatic Colorectal Cancer. Value Health. 2020;23:S43. doi:10.1016/j.jval.2020.04.1608
   PubMed Web of Science ®Google Scholar
• Kashiwa M, Matsushita R. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. Clin. Ther. 2020;42(7):1376–1387. doi:10.1016/j.clinthera.2020.05.014
   PubMed Web of Science ®Google Scholar
• Kimura M, Usami E, Iwai M, Go M, Teramachi H, Yoshimura T. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Mol Clin Oncol. 2016;5(5):635–640. doi:10.3892/mco.2016.1020
   PubMedGoogle Scholar
• Giuliani J, Fiorica F, Ponturo G, Azzurro M, Ruzzenente A, Bonetti A. Dose-escalation strategy in refractory metastatic colorectal cancer: a change in terms of cost-effectiveness. J Oncol Pharm Pract. 2021;27(4):974–977. doi:10.1177/1078155221992546
   PubMed Web of Science ®Google Scholar
• Bullement A, Underhill S, Fougeray R, Hatswell AJ. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. Clin Colorectal Cancer. 2018;17(1):e143–e151. doi:10.1016/j.clcc.2017.09.001
   PubMed Web of Science ®Google Scholar
• Gourzoulidis G, Maniadakis N, Petrakis D, Souglakos J, Pentheroudakis G, Kourlaba G. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. J Comp Eff Res. 2019;8(3):133–142. doi:10.2217/cer-2018-0076
   PubMed Web of Science ®Google Scholar
• Mlcoch T, Tereza H, Zadak J, Vesela S, Marian M, Dolezal T. Regorafenib in Metastatic Colorectal Cancer: cost-Effectiveness Analysis Based on Propensity Score Weighted Cohort of Czech Registry. Value Health. 2018;21.
   Google Scholar
• Van Cutsem E, Martinelli E, Cascinu S, et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019;24(2):185–192. doi:10.1634/theoncologist.2018-0072
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet. 2013;381(9863):303–312. doi:10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of Tas-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919. doi:10.1056/NEJMoa1414325
   PubMed Web of Science ®Google Scholar
• Per P, Mette Y, Sören M, et al. Tas-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412–420. doi:10.1016/S1470-2045(19)30827-7
   PubMed Web of Science ®Google Scholar